Class information for: |
Basic class information |
| ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
|---|---|---|---|
| 14445 | 703 | 38.8 | 57% |
Classes in level above (level 2) |
Terms with highest relevance score |
| Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|---|
| 1 | DIABET CELL BIOL | Address | 8 | 62% | 1% | 8 |
| 2 | CELL BIOL DIABET | Address | 7 | 39% | 2% | 13 |
| 3 | LOW DENSITY LIPOPROTEIN RETENTION | Author keyword | 4 | 75% | 0% | 3 |
| 4 | DIABET COMPLICAT GRP | Address | 4 | 29% | 2% | 11 |
| 5 | LIPOPROTEIN PROTEOGLYCAN COMPLEXES | Author keyword | 3 | 100% | 0% | 3 |
| 6 | LDL BINDING | Author keyword | 2 | 38% | 1% | 5 |
| 7 | INNOVAT MANAGING DIRECT | Address | 2 | 67% | 0% | 2 |
| 8 | PDGF RECEPTOR PHOSPHORYLATION | Author keyword | 2 | 67% | 0% | 2 |
| 9 | LDL RETENTION | Author keyword | 2 | 50% | 0% | 3 |
| 10 | METAB EXERCISE DIS PROGRAM | Address | 1 | 50% | 0% | 2 |
Web of Science journal categories |
Author Key Words |
Key Words Plus |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | ARTERIAL PROTEOGLYCANS | 58 | 57% | 10% | 69 |
| 2 | CELL PROTEOGLYCANS | 6 | 80% | 1% | 4 |
| 3 | WALL PROTEOGLYCANS | 6 | 80% | 1% | 4 |
| 4 | WALL DERIVED PROTEOGLYCAN | 6 | 100% | 1% | 4 |
| 5 | INCREASED BINDING | 5 | 54% | 1% | 7 |
| 6 | CHOLESTERYL ESTER ACCUMULATION | 5 | 20% | 3% | 24 |
| 7 | AORTIC GLYCOSAMINOGLYCANS | 4 | 75% | 0% | 3 |
| 8 | COMPLEXING PROTEOGLYCAN | 4 | 75% | 0% | 3 |
| 9 | GLYCOSAMINOGLYCAN COMPOSITION | 4 | 46% | 1% | 6 |
| 10 | CHONDROITIN 6 SULFATE PROTEOGLYCAN | 3 | 100% | 0% | 3 |
Journals |
Reviews |
| Title | Publ. year | Cit. | Active references | % act. ref. to same field |
|---|---|---|---|---|
| Retention of atherogenic lipoproteins in the artery wall and its role in atherogenesis | 2012 | 15 | 68 | 46% |
| Proteoglycans in atherosclerosis and restenosis - Key roles for versican | 2004 | 157 | 122 | 39% |
| Subendothelial lipoprotein retention as the initiating process in atherosclerosis - Update and therapeutic implications | 2007 | 378 | 113 | 22% |
| Early atherosclerosis in humans: role of diffuse intimal thickening and extracellular matrix proteoglycans | 2008 | 64 | 86 | 35% |
| Association of apo B lipoproteins with arterial proteoglycans: Pathological significance and molecular basis | 1998 | 187 | 97 | 46% |
| Regulation of glycosaminoglycan structure and atherogenesis | 2004 | 39 | 43 | 60% |
| Glycosaminoglycans as Key Molecules in Atherosclerosis: The Role of Versican and Hyaluronan | 2010 | 14 | 68 | 40% |
| Cellular consequences of the association of ApoB lipoproteins with proteoglycans - Potential contribution to atherogenesis | 1997 | 94 | 82 | 50% |
| Proteoglycan mediated lipoprotein retention: A mechanism of diabetic atherosclerosis | 2008 | 20 | 107 | 45% |
| CELL BIOLOGY OF ARTERIAL PROTEOGLYCANS | 1989 | 327 | 223 | 28% |
Address terms |
| Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | DIABET CELL BIOL | 8 | 62% | 1.1% | 8 |
| 2 | CELL BIOL DIABET | 7 | 39% | 1.8% | 13 |
| 3 | DIABET COMPLICAT GRP | 4 | 29% | 1.6% | 11 |
| 4 | INNOVAT MANAGING DIRECT | 2 | 67% | 0.3% | 2 |
| 5 | METAB EXERCISE DIS PROGRAM | 1 | 50% | 0.3% | 2 |
| 6 | PRECLIN S BIOCHEM | 1 | 100% | 0.3% | 2 |
| 7 | DISCIPLINE PHARM | 1 | 12% | 1.4% | 10 |
| 8 | ORG FRONTIER | 1 | 33% | 0.3% | 2 |
| 9 | CENT EASTERN CLIN ALFRED HLTH | 1 | 50% | 0.1% | 1 |
| 10 | CIENCIAS BIOMED BIOQUIM MED | 1 | 50% | 0.1% | 1 |
Related classes at same level (level 1) |
| Rank | Relatedness score | Related classes |
|---|---|---|
| 1 | 0.0000271904 | ELECTRONEGATIVE LDL//ELECTRONEGATIVE LOW DENSITY LIPOPROTEIN//ENZYMATICALLY MODIFIED LDL |
| 2 | 0.0000180797 | C PL RATIO//C PL//FATEBENEFRATELLI FDN |
| 3 | 0.0000161791 | AGE RELATED DECREASE IN PGI2 PRODUCTION//EN FACE TECHNIQUE//15 ISOPROSTANE F 2T |
| 4 | 0.0000135408 | DECORIN//LUMICAN//BIGLYCAN |
| 5 | 0.0000134745 | BIOCHEM PHYSIOL NUTR SCITORRE BIOL//HEPARIN LIKE ANTICOAGULANTS//IST PLURIDISCIPLINARE FISIOL UMANA |
| 6 | 0.0000134732 | PROTEOGLYCAN RECEPTOR//PROTEOHEPARAN SULFATE//ARTERIOSCLEROSIS MODEL |
| 7 | 0.0000128995 | VESSEL SIMULATING FLOW THROUGH CELL//LOCAL PHARMACOKINETICS//PATHOPHARMACOL UNIT |
| 8 | 0.0000124661 | VERSICAN//G3 DOMAIN//LINK PROTEIN |
| 9 | 0.0000098443 | SERGLYCIN//SERGLYCIN PROTEOGLYCAN//KIDNEY SECT |
| 10 | 0.0000093168 | CTHRC1//COLLAGEN TRIPLE HELIX REPEAT CONTAINING 1//CAROTID ARTERY RESTENOSIS |